Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?

Advances in Biological Regulation

Volumn 59, Issue , 2015, Pages 19-35

  Baer, Romain ^a   Cintas, Célia ^a   Therville, Nicole ^a   Guillermet Guibert, Julie ^a  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

Author keywords

Acinar cell transformation; Cell signalling; Class I isoforms; Genetically modified mouse models; Mutant Kras; Pancreatic cancer; PI3K Akt pathway

Indexed keywords

ISOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; PANCREAS TUMOR; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84942551162     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2015.05.001     Document Type: Review

References (123)

1. Abdollahi A., Schwager C., Kleeff J., Esposito I., Domhan S., Peschke P., et al. Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A 2007, 104(31):12890-12895.
2. Alagesan B., Contino G., Guimaraes A.R., Corcoran R.B., Deshpande V., Wojtkiewicz G.R., et al. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res 2015, 21(2):396-404.
3. Albury T.M., Pandey V., Gitto S.B., Dominguez L., Spinel L.P., Talarchek J., et al. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression. Neoplasia 2015, 17(2):175-182.
4. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53(4):549-554.
5. Altomare D.A., Tanno S., De Rienzo A., Klein-Szanto A.J., Skele K.L., Hoffman J.P., et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 2002, 87(4):470-476.
6. Apte M.V., Wilson J.S., Lugea A., Pandol S.J. A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology 2013, 144(6):1210-1219.
7. Ardito C.M., Gruner B.M., Takeuchi K.K., Lubeseder-Martellato C., Teichmann N., Mazur P.K., et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012, 22(3):304-317.
8. Asano T., Yao Y., Zhu J., Li D., Abbruzzese J.L., Reddy S.A. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 2004, 23(53):8571-8580.
9. Baer R., Cintas C., Dufresne M., Cassant-Sourdy S., Schonhuber N., Planque L., et al. Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110alpha. Genes Dev 2014, 28(23):2621-2635.
10. Berenjeno I.M., Guillermet-Guibert J., Pearce W., Gray A., Fleming S., Vanhaesebroeck B. Both p110alpha and p110beta isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem J 2012, 442(1):151-159.
11. Biankin A.V., Waddell N., Kassahn K.S., Gingras M.C., Muthuswamy L.B., Johns A.L., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491(7424):399-405.
12. Bondar V.M., Sweeney-Gotsch B., Andreeff M., Mills G.B., McConkey D.J. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002, 1(12):989-997.
13. Bousquet C., Guillermet-Guibert J., Saint-Laurent N., Archer-Lahlou E., Lopez F., Fanjul M., et al. Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. EMBO J 2006, 25(17):3943-3954.
14. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15(6):2403-2413.
15. Campbell P.M., Groehler A.L., Lee K.M., Ouellette M.M., Khazak V., Der C.J. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 2007, 67(5):2098-2106.
16. Cao P., Maira S.M., Garcia-Echeverria C., Hedley D.W. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer 2009, 100(8):1267-1276.
17. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118(9):3065-3074.
18. Castellano E., Sheridan C., Thin M.Z., Nye E., Spencer-Dene B., Diefenbacher M.E., et al. Requirement for interaction of PI3-kinase p110alpha with RAS in lung tumor maintenance. Cancer Cell 2013, 24(5):617-630.
19. Chalabi-Dchar M., Cassant-Sourdy S., Duluc C., Fanjul M., Lulka H., Samain R., et al. Loss of somatostatin receptor subtype 2 promotes growth of KRAS-induced pancreatic tumors in mice by activating PI3K signaling and overexpression of CXCL16. Gastroenterology 2015, 148(7):1452-1465.
20. Cheng J.Q., Ruggeri B., Klein W.M., Sonoda G., Altomare D.A., Watson D.K., et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A 1996, 93(8):3636-3641.
21. Chow J.Y., Quach K.T., Cabrera B.L., Cabral J.A., Beck S.E., Carethers J.M. RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. Carcinogenesis 2007, 28(11):2321-2327.
22. Ciuffreda L., Falcone I., Incani U.C., Del Curatolo A., Conciatori F., Matteoni S., et al. PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Adv Biol Regul 2014, 56:66-80.
23. Collins M.A., Yan W., Sebolt-Leopold J.S., Pasca di Magliano M. MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice. Gastroenterology 2014, 146(3). 822-834.e827.
24. Collisson E.A., Trejo C.L., Silva J.M., Gu S., Korkola J.E., Heiser L.M., et al. A central role for RAF-->MEK-->ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2012, 2(8):685-693.
25. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364(19):1817-1825.
26. Daniluk J., Liu Y., Deng D., Chu J., Huang H., Gaiser S., et al. An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 2012, 122(4):1519-1528.
27. Dbouk H.A., Pang H., Fiser A., Backer J.M. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2010, 107(46):19897-19902.
28. Diersch S., Wenzel P., Szameitat M., Eser P., Paul M.C., Seidler B., et al. Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. Oncotarget 2013, 4(2):277-288.
29. Duluc C., Moatassim-Billah S., Chalabi-Dchar M., Perraud A., Samain R., Breibach F., et al. Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol Med 2015, 7(6):735-753.
30. Ebert M.P., Fei G., Schandl L., Mawrin C., Dietzmann K., Herrera P., et al. Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br J Cancer 2002, 86(2):257-262.
31. Edling C.E., Selvaggi F., Buus R., Maffucci T., Di Sebastiano P., Friess H., et al. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res 2010, 16(20):4928-4937.
32. Elghazi L., Weiss A.J., Barker D.J., Callaghan J., Staloch L., Sandgren E.P., et al. Regulation of pancreas plasticity and malignant transformation by Akt signaling. Gastroenterology 2009, 136(3):1091-1103.
33. Eser S., Reiff N., Messer M., Seidler B., Gottschalk K., Dobler M., et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 2013, 23(3):406-420.
34. Feldmann G., Beaty R., Hruban R.H., Maitra A. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg 2007, 14(3):224-232.
35. Fitzgerald T.L., McCubrey J.A. Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. Adv Biol Regul 2014, 56:45-50.
36. Foo W.C., Rashid A., Wang H., Katz M.H., Lee J.E., Pisters P.W., et al. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum Pathol 2013, 44(6):1024-1030.
37. Foukas L.C., Berenjeno I.M., Gray A., Khwaja A., Vanhaesebroeck B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A 2010, 107(25):11381-11386.
38. Fritsch R., de Krijger I., Fritsch K., George R., Reason B., Kumar M.S., et al. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 2013, 153(5):1050-1063.
39. Fruman D.A., Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014, 13(2):140-156.
40. Fukuda A., Wang S.C., Morris J.P.T., Folias A.E., Liou A., Kim G.E., et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011, 19(4):441-455.
41. Garmy-Susini B., Avraamides C.J., Desgrosellier J.S., Schmid M.C., Foubert P., Ellies L.G., et al. PI3Kalpha activates integrin alpha4beta1 to establish a metastatic niche in lymph nodes. Proc Natl Acad Sci U S A 2013, 110(22):9042-9047.
42. Garrido-Laguna I., Tan A.C., Uson M., Angenendt M., Ma W.W., Villaroel M.C., et al. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer 2010, 103(5):649-655.
43. Gopal A.K., Kahl B.S., de Vos S., Wagner-Johnston N.D., Schuster S.J., Jurczak W.J., et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014, 370(11):1008-1018.
44. Graupera M., Guillermet-Guibert J., Foukas L.C., Phng L.K., Cain R.J., Salpekar A., et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008, 453(7195):662-666.
45. Gritsman K., Yuzugullu H., Von T., Yan H., Clayton L., Fritsch C., et al. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110alpha. J Clin Invest 2014, 124(4):1794-1809.
46. Guerra C., Schuhmacher A.J., Canamero M., Grippo P.J., Verdaguer L., Perez-Gallego L., et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007, 11(3):291-302.
47. Guerra C., Collado M., Navas C., Schuhmacher A.J., Hernandez-Porras I., Canamero M., et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 2011, 19(6):728-739.
48. Guillermet J., Saint-Laurent N., Rochaix P., Cuvillier O., Levade T., Schally A.V., et al. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci U S A 2003, 100(1):155-160.
49. Guillermet-Guibert J., Saint-Laurent N., Davenne L., Rochaix P., Cuvillier O., Culler M.D., et al. Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways. Cell Death Differ 2007, 14(2):197-208.
50. Guillermet-Guibert J., Bjorklof K., Salpekar A., Gonella C., Ramadani F., Bilancio A., et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A 2008, 105(24):8292-8297.
51. Gupta S., Ramjaun A.R., Haiko P., Wang Y., Warne P.H., Nicke B., et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 2007, 129(5):957-968.
52. Hezel A.F., Kimmelman A.C., Stanger B.Z., Bardeesy N., Depinho R.A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006, 20(10):1218-1249.
53. Hill R., Calvopina J.H., Kim C., Wang Y., Dawson D.W., Donahue T.R., et al. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res 2010, 70(18):7114-7124.
54. Hingorani S.R., Petricoin E.F., Maitra A., Rajapakse V., King C., Jacobetz M.A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4(6):437-450.
55. Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7(5):469-483.
56. Hirsch E., Katanaev V.L., Garlanda C., Azzolino O., Pirola L., Silengo L., et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000, 287(5455):1049-1053.
57. Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013, 369(18):1691-1703.
58. Houbracken I., de Waele E., Lardon J., Ling Z., Heimberg H., Rooman I., et al. Lineage tracing evidence for transdifferentiation of acinar to duct cells and plasticity of human pancreas. Gastroenterology 2011, 141(2):731-741. 741.e1-4.
59. Hwang R.F., Yokoi K., Bucana C.D., Tsan R., Killion J.J., Evans D.B., et al. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2003, 9(17):6534-6544.
60. Javle M.M., Shroff R.T., Xiong H., Varadhachary G.A., Fogelman D., Reddy S.A., et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 2010, 10:368.
61. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
62. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321(5897):1801-1806.
63. Junttila M.R., Devasthali V., Cheng J.H., Castillo J., Metcalfe C., Clermont A.C., et al. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic Cancer. Mol Cancer Ther 2015, 14(1):40-47.
64. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006, 6(5):392-401.
65. Kang S., Denley A., Vanhaesebroeck B., Vogt P.K. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2006, 103(5):1289-1294.
66. Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006, 125(4):733-747.
67. Kodaki T., Woscholski R., Hallberg B., Rodriguez-Viciana P., Downward J., Parker P.J. The activation of phosphatidylinositol 3-kinase by Ras. Curr Biol 1994, 4(9):798-806.
68. Kong B., Wu W., Cheng T., Schlitter A.M., Qian C., Bruns P., et al. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. Gut 2015 Jan 19.
69. Koorstra J.B., Karikari C.A., Feldmann G., Bisht S., Rojas P.L., Offerhaus G.J., et al. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 2009, 8(7):618-626.
70. Lesina M., Kurkowski M.U., Ludes K., Rose-John S., Treiber M., Kloppel G., et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011, 19(4):456-469.
71. Ma J., Sawai H., Ochi N., Matsuo Y., Xu D., Yasuda A., et al. PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells. Mol Cell Biochem 2009, 331(1-2):161-171.
72. Mathieu A., Clerc P., Portolan G., Bierkamp C., Lulka H., Pradayrol L., et al. Transgenic expression of CCK2 receptors sensitizes murine pancreatic acinar cells to carcinogen-induced preneoplastic lesions formation. Int J Cancer 2005, 115(1):46-54.
73. Molina-Arcas M., Hancock D.C., Sheridan C., Kumar M.S., Downward J. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov 2013, 3(5):548-563.
74. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25(15):1960-1966.
75. Morfoisse F., Kuchnio A., Frainay C., Gomez-Brouchet A., Delisle M.B., Marzi S., et al. Hypoxia induces VEGF-C expression in metastatic tumor cells via a HIF-1alpha-independent translation-mediated mechanism. Cell Rep 2014, 6(1):155-167.
76. Morran D.C., Wu J., Jamieson N.B., Mrowinska A., Kalna G., Karim S.A., et al. Targeting mTOR dependency in pancreatic cancer. Gut 2014, 63(9):1481-1489.
77. Morris J.P.T., Wang S.C., Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010, 10(10):683-695.
78. Morton J.P., Mongeau M.E., Klimstra D.S., Morris J.P., Lee Y.C., Kawaguchi Y., et al. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci U S A 2007, 104(12):5103-5108.
79. Murillo M.M., Zelenay S., Nye E., Castellano E., Lassailly F., Stamp G., et al. RAS interaction with PI3K p110alpha is required for tumor-induced angiogenesis. J Clin Invest 2014, 124(8):3601-3611.
80. Navas C., Hernandez-Porras I., Schuhmacher A.J., Sibilia M., Guerra C., Barbacid M. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 2012, 22(3):318-330.
81. Ng S.S., Tsao M.S., Nicklee T., Hedley D.W. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001, 7(10):3269-3275.
82. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66(3):1500-1508.
83. Okami K., Wu L., Riggins G., Cairns P., Goggins M., Evron E., et al. Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res 1998, 58(3):509-511.
84. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324(5933):1457-1461.
85. Perugini R.A., McDade T.P., Vittimberga F.J., Callery M.P. Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 2000, 90(1):39-44.
86. Pettazzoni P., Viale A., Shah P., Carugo A., Ying H., Wang H., et al. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res 2015, 75(6):1091-1101.
87. Pinho A.V., Rooman I., Reichert M., De Medts N., Bouwens L., Rustgi A.K., et al. Adult pancreatic acinar cells dedifferentiate to an embryonic progenitor phenotype with concomitant activation of a senescence programme that is present in chronic pancreatitis. Gut 2011, 60(7):958-966.
88. Porta M., Fabregat X., Malats N., Guarner L., Carrato A., de Miguel A., et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol 2005, 7(5):189-197.
89. Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011, 11(11):761-774.
90. Reichert M., Saur D., Hamacher R., Schmid R.M., Schneider G. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res 2007, 67(9):4149-4156.
91. Rodon J., Dienstmann R., Serra V., Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013, 10(3):143-153.
92. Rodriguez-Viciana P., Warne P.H., Dhand R., Vanhaesebroeck B., Gout I., Fry M.J., et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370(6490):527-532.
93. Rodriguez-Viciana P., Warne P.H., Vanhaesebroeck B., Waterfield M.D., Downward J. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J 1996, 15(10):2442-2451.
94. Rodriguez-Viciana P., Warne P.H., Khwaja A., Marte B.M., Pappin D., Das P., et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997, 89(3):457-467.
95. Ryan D.P., Hong T.S., Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014, 371(22):2140-2141.
96. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304(5670):554.
97. Schild C., Wirth M., Reichert M., Schmid R.M., Saur D., Schneider G. PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells. Mol Carcinog 2009, 48(12):1149-1158.
98. Schlieman M.G., Fahy B.N., Ramsamooj R., Beckett L., Bold R.J. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003, 89(11):2110-2115.
99. Schmid M.C., Avraamides C.J., Dippold H.C., Franco I., Foubert P., Ellies L.G., et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 2011, 19(6):715-727.
100. Schmit F., Utermark T., Zhang S., Wang Q., Von T., Roberts T.M., et al. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A 2014, 111(17):6395-6400.
101. Shi G., DiRenzo D., Qu C., Barney D., Miley D., Konieczny S.F. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia. Oncogene 2013, 32(15):1950-1958.
102. Soares H.P., Ming M., Mellon M., Young S.H., Han L., Sinnet-Smith J., et al. Dual PI3K/mTOR inhibitors induce rapid overactivation of the MEK/ERK pathway in human pancreatic cancer cells through suppression of mTORC2. Mol Cancer Ther 2015, 14(4):1014-1023.
103. Soler A., Serra H., Pearce W., Angulo A., Guillermet-Guibert J., Friedman L.S., et al. Inhibition of the p110alpha isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. J Exp Med 2013, 210(10):1937-1945.
104. Song X., Wang H., Logsdon C.D., Rashid A., Fleming J.B., Abbruzzese J.L., et al. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 2011, 117(4):734-743.
105. Stanger B.Z., Stiles B., Lauwers G.Y., Bardeesy N., Mendoza M., Wang Y., et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 2005, 8(3):185-195.
106. Suire S., Condliffe A.M., Ferguson G.J., Ellson C.D., Guillou H., Davidson K., et al. Gbetagammas and the Ras binding domain of p110gamma are both important regulators of PI(3)Kgamma signalling in neutrophils. Nat Cell Biol 2006, 8(11):1303-1309.
107. Takeda A., Osaki M., Adachi K., Honjo S., Ito H. Role of the phosphatidylinositol 3'-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas 2004, 28(3):353-358.
108. Thorpe L.M., Yuzugullu H., Zhao J.J. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 2015, 15(1):7-24.
109. Toker A., Marmiroli S. Signaling specificity in the Akt pathway in biology and disease. Adv Biol Regul 2014, 55:28-38.
110. Tomizawa M., Shinozaki F., Sugiyama T., Yamamoto S., Sueishi M., Yoshida T. Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer. World J Gastroenterol 2010, 16(15):1854-1858.
111. Vanhaesebroeck B., Guillermet-Guibert J., Graupera M., Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010, 11(5):329-341.
112. Vasudevan K.M., Burikhanov R., Goswami A., Rangnekar V.M. Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras. Cancer Res 2007, 67(21):10343-10350.
113. Venkannagari S., Fiskus W., Peth K., Atadja P., Hidalgo M., Maitra A., et al. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Oncotarget 2012, 3(11):1416-1427.
114. Vilar E., Perez-Garcia J., Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 2011, 10(3):395-403.
115. Waddell N., Pajic M., Patch A.M., Chang D.K., Kassahn K.S., Bailey P., et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015, 518(7540):495-501.
116. Whitehead M.A., Bombardieri M., Pitzalis C., Vanhaesebroeck B. Isoform-selective induction of human p110delta PI3K expression by TNFalpha: identification of a new and inducible PIK3CD promoter. Biochem J 2012, 443(3):857-867.
117. Wolpin B.M., Hezel A.F., Abrams T., Blaszkowsky L.S., Meyerhardt J.A., Chan J.A., et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009, 27(2):193-198.
118. Wu C.Y., Carpenter E.S., Takeuchi K.K., Halbrook C.J., Peverley L.V., Bien H., et al. PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice. Gastroenterology 2014, 147(6):1405-1416.e7.
119. Yamamoto S., Tomita Y., Hoshida Y., Morooka T., Nagano H., Dono K., et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004, 10(8):2846-2850.
120. Ying H., Elpek K.G., Vinjamoori A., Zimmerman S.M., Chu G.C., Yan H., et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaB-cytokine network. Cancer Discov 2011, 1(2):158-169.
121. Zhang X., Vadas O., Perisic O., Anderson K.E., Clark J., Hawkins P.T., et al. Structure of lipid kinase p110beta/p85beta elucidates an unusual SH2-domain-mediated inhibitory mechanism. Mol Cell 2011, 41(5):567-578.
122. Zhang Y., Yan W., Collins M.A., Bednar F., Rakshit S., Zetter B.R., et al. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res 2013, 73(20):6359-6374.
123. Zhong H., Sanchez C., Spitrzer D., Plambeck-Suess S., Gibbs J., Hawkins W.G., et al. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. PLoS One 2013, 8(10):e77243.